Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim

Jessica Chang; Pinar Karaca-Mandic; Ronald S. Go; Stephen Schondelmeyer; Daniel J Weisdorf; Molly Moore Jeffery

doi:10.37765/ajmc.2023.89363

Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim

Jessica Chang, Pinar Karaca-Mandic, Ronald S. Go, Stephen Schondelmeyer, Daniel J Weisdorf, Molly Moore Jeffery

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non–rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study offers a first look at an underappreciated source of disparities in access to lower-cost medications such as biosimilars. Results from our study reveal opportunities for targeted policies to encourage adoption of lower-cost treatments, particularly among hospitals that serve rural communities where patients often have fewer choices in care site.

Original language	English (US)
Pages (from-to)	E155-E158
Journal	American Journal of Managed Care
Volume	29
Issue number	5
DOIs	https://doi.org/10.37765/ajmc.2023.89363
State	Published - May 2023

Bibliographical note

Funding Information:
Author Disclosures: Dr Karaca-Mandic is the principal investigator and Dr Jeffery is a coinvestigator of the American Cancer Society grant that funded this study. Dr Karaca-Mandic also reports receipt of unrelated personal fees from Koya Medical and Mayo Clinic; receipt of unrelated grants from the Agency for Healthcare Research and Quality,the National Institute for HealthCare Management, the National Institute on Drug Abuse/National Institutes of Health, the Robert Wood Johnson Foundation, and the United Health Foundation; and serving in an executive position and holding equity in XanthosHealth LLC, which is developing health information technology in oncology; Dr Karaca-Mandic’s interests have been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. Dr Weisdorf reports receiving research support from FATE and Incyte and receiving lecture fees for a presentation on graft-vs-host disease, all outside this work. The remaining authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

Publisher Copyright:
© 2023 Ascend Media. All rights reserved.

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

Publisher link

10.37765/ajmc.2023.89363

Find It

Find It at U of M Libraries

Cite this

@article{57d8b7319609430894c2a1410f44f471,

title = "Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim",

abstract = "In this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non–rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study offers a first look at an underappreciated source of disparities in access to lower-cost medications such as biosimilars. Results from our study reveal opportunities for targeted policies to encourage adoption of lower-cost treatments, particularly among hospitals that serve rural communities where patients often have fewer choices in care site.",

author = "Jessica Chang and Pinar Karaca-Mandic and Go, {Ronald S.} and Stephen Schondelmeyer and Weisdorf, {Daniel J} and Jeffery, {Molly Moore}",

note = "Funding Information: Author Disclosures: Dr Karaca-Mandic is the principal investigator and Dr Jeffery is a coinvestigator of the American Cancer Society grant that funded this study. Dr Karaca-Mandic also reports receipt of unrelated personal fees from Koya Medical and Mayo Clinic; receipt of unrelated grants from the Agency for Healthcare Research and Quality,the National Institute for HealthCare Management, the National Institute on Drug Abuse/National Institutes of Health, the Robert Wood Johnson Foundation, and the United Health Foundation; and serving in an executive position and holding equity in XanthosHealth LLC, which is developing health information technology in oncology; Dr Karaca-Mandic{\textquoteright}s interests have been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. Dr Weisdorf reports receiving research support from FATE and Incyte and receiving lecture fees for a presentation on graft-vs-host disease, all outside this work. The remaining authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article. Publisher Copyright: {\textcopyright} 2023 Ascend Media. All rights reserved.",

year = "2023",

month = may,

doi = "10.37765/ajmc.2023.89363",

language = "English (US)",

volume = "29",

pages = "E155--E158",

journal = "American Journal of Managed Care",

issn = "1088-0224",

publisher = "Ascend Media",

number = "5",

}

TY - JOUR

T1 - Provider Barriers in Uptake of Biosimilars

T2 - Case Study on Filgrastim

AU - Chang, Jessica

AU - Karaca-Mandic, Pinar

AU - Go, Ronald S.

AU - Schondelmeyer, Stephen

AU - Weisdorf, Daniel J

AU - Jeffery, Molly Moore

N1 - Funding Information: Author Disclosures: Dr Karaca-Mandic is the principal investigator and Dr Jeffery is a coinvestigator of the American Cancer Society grant that funded this study. Dr Karaca-Mandic also reports receipt of unrelated personal fees from Koya Medical and Mayo Clinic; receipt of unrelated grants from the Agency for Healthcare Research and Quality,the National Institute for HealthCare Management, the National Institute on Drug Abuse/National Institutes of Health, the Robert Wood Johnson Foundation, and the United Health Foundation; and serving in an executive position and holding equity in XanthosHealth LLC, which is developing health information technology in oncology; Dr Karaca-Mandic’s interests have been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. Dr Weisdorf reports receiving research support from FATE and Incyte and receiving lecture fees for a presentation on graft-vs-host disease, all outside this work. The remaining authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article. Publisher Copyright: © 2023 Ascend Media. All rights reserved.

PY - 2023/5

Y1 - 2023/5

N2 - In this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non–rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study offers a first look at an underappreciated source of disparities in access to lower-cost medications such as biosimilars. Results from our study reveal opportunities for targeted policies to encourage adoption of lower-cost treatments, particularly among hospitals that serve rural communities where patients often have fewer choices in care site.

AB - In this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non–rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study offers a first look at an underappreciated source of disparities in access to lower-cost medications such as biosimilars. Results from our study reveal opportunities for targeted policies to encourage adoption of lower-cost treatments, particularly among hospitals that serve rural communities where patients often have fewer choices in care site.

UR - http://www.scopus.com/inward/record.url?scp=85160456988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160456988&partnerID=8YFLogxK

U2 - 10.37765/ajmc.2023.89363

DO - 10.37765/ajmc.2023.89363

M3 - Article

C2 - 37229790

AN - SCOPUS:85160456988

SN - 1088-0224

VL - 29

SP - E155-E158

JO - American Journal of Managed Care

JF - American Journal of Managed Care

IS - 5

ER -

Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim

Abstract

Bibliographical note

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this